See more : Showa Paxxs Corporation (3954.T) Income Statement Analysis – Financial Results
Complete financial analysis of Verrica Pharmaceuticals Inc. (VRCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verrica Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Capstone Green Energy Corporation (CGRN) Income Statement Analysis – Financial Results
- Fortress Transportation and Infrastructure Investors LLC (FTAI-PB) Income Statement Analysis – Financial Results
- CB Industrial Product Holding Berhad (CIHPF) Income Statement Analysis – Financial Results
- RAVENO Capital AG (TUF.DE) Income Statement Analysis – Financial Results
- Selena FM S.A. (SEL.WA) Income Statement Analysis – Financial Results
Verrica Pharmaceuticals Inc. (VRCA)
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.12M | 9.03M | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 746.00K | 725.00K | 472.00K | 229.00K | 257.20K | 20.29K | 0.00 | 0.00 |
| Gross Profit | 4.38M | 8.31M | 11.53M | -229.00K | -257.20K | -20.29K | 0.00 | 0.00 |
| Gross Profit Ratio | 85.44% | 91.97% | 96.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.30M | 12.20M | 15.93M | 15.67M | 15.44M | 12.83M | 3.73M | 1.71M |
| General & Administrative | 0.00 | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.31M | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Other Expenses | 2.54M | -58.00K | 0.00 | -1.00K | 1.87M | -1.00K | 0.00 | 0.00 |
| Operating Expenses | 70.14M | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Cost & Expenses | 70.88M | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Interest Income | 2.74M | 476.00K | 123.00K | 521.00K | 1.88M | 1.23M | 0.00 | 0.00 |
| Interest Expense | 3.96M | 2.17M | 4.30M | 3.03M | 0.00 | 0.00 | 2.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 718.00K | 472.00K | 229.00K | 257.20K | 20.29K | 4.46M | 1.91M |
| EBITDA | -62.20M | -21.60M | -30.31M | -39.43M | -30.08M | -20.63M | -4.46M | -1.91M |
| EBITDA Ratio | -1,213.84% | -231.16% | -256.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.76M | -21.30M | -30.91M | -40.18M | -30.08M | -21.88M | -4.46M | -1.91M |
| Operating Income Ratio | -1,283.35% | -235.78% | -257.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.24M | -3.19M | -4.17M | -2.51M | 1.87M | 1.23M | -2.00K | 0.00 |
| Income Before Tax | -67.00M | -24.49M | -35.08M | -42.69M | -28.21M | -20.65M | -4.46M | -1.91M |
| Income Before Tax Ratio | -1,307.47% | -271.11% | -292.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.19M | 3.82M | 2.80M | -257.00K | 1.23M | -4.46M | -1.91M |
| Net Income | -67.00M | -27.68M | -38.90M | -45.50M | -27.95M | -20.65M | -4.46M | -1.91M |
| Net Income Ratio | -1,307.47% | -306.44% | -324.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| EPS Diluted | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
| Weighted Avg Shares Out (Dil) | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Source: https://incomestatements.info
Category: Stock Reports